mechanisms of resistance to 5-azacytidine/decitabine in mds-aml
Published 8 years ago • 157 plays • Length 7:49Download video MP4
Download video MP3
Similar videos
-
1:37
dr. saunthararajah on mechanisms of resistance to 5-azacytidine/decitabine in mds-aml
-
3:42
mechanisms of resistance to venetoclax in aml and methods being explored to overcome these
-
2:40
safety and efficacy of sabatolimab plus azacitidine or decitabine in patients with hr-mds and aml
-
4:07
phase ii study: low dose decitabine vs. low dose azacitidine (low or intermediate-1-risk mds)
-
3:03
venetoclax and 5-azacytidine for the treatment of mds and cmml
-
4:15
resistance mechanisms in aml and treatment decisions
-
2:21
decitabine mechanism of action
-
5:36
david sallman: magrolimab plus azacitidine effective in mds and aml
-
3:21
mode of action of hypomethylating agents for mds
-
5:22
magrolimab azacitidine in mds and aml
-
2:56
sequential azacitidine and high-dose lenalidomide for relapsed and refractory high-risk mds and aml
-
2:02
what are hypomethylating agents and when are they used for mds?
-
2:46
azacitidine w/ lenalidomide or with vorinostat vs. azacitidine monotherapy: higher-risk mds and cmml
-
3:34
anti-cd47 antibodies & azacitidine for aml and mds
-
19:18
understanding efficacy of azacitidine in different mds subgroups
-
2:37
immune checkpoint inhibitors for aml: mechanism, rationale & using azacitidine to boost response
-
4:44
establishing the clinical benchmark of azacitidine in patients with mds
-
6:21
decitabine and venetoclax for aml
-
4:59
aml: optimizing selection and use of venetoclax azacitidine